Form 8-K · Current Report · Filed 2025-02-20
Johnson & Johnson Completed Public Offerings of Various Notes
On February 20, 2025, Johnson & Johnson completed the public offerings of various notes, including $750,000,000 aggregate principal amount of 4.500% Notes due 2027, $750,000,000 aggregate principal amount of 4.550% Notes due 2028, $1,000,000,000 aggregate principal amount of 4.700% Notes due 2030, $1,250,000,000 aggregate principal amount of 4.850% Notes due 2032, and $1,250,000,000 aggregate principal amount of 5.000% Notes due 2035, under the Company's Registration Statement on Form S-3.
- Filer
- Johnson & Johnson JNJ · NYSE
- Filed
- Accession
- 0001193125-25-030851
- CIK
- 0000200406
- Signal
- Medium impactHealthcare
- Source
- Official filing on sec.gov ↗
Details
The offerings were made in connection with an underwriting agreement entered on February 18, 2025.
Items reported
Other Events
Financial Statements and Exhibits
Market reaction
Close before filing
$157.89
Next session
+2.8%
Since filing
+62.4%
Latest close
$256.35
What happened, not what will happen — closing prices around the filing date.
Precedent
Previous filings from JNJ reporting the same item, with the next session's move:
Exhibits (10)
About Johnson & Johnson
Johnson & Johnson is a multinational corporation engaged in the research, development, production, and sale of a broad range of healthcare products. Primarily known for its pharmaceuticals, medical devices, and consumer health products, Johnson & Johnson has a significant presence in the global healthcare industry. It develops medications for a variety of fields such as immunology, oncology, neurology, infectious diseases, and vaccines. The company also produces a wide array of medical devices for surgery, orthopedics, and cardiovascular health. In addition to pharmaceuticals, Johnson & Johnson is renowned for its consumer health products, including baby care, skin and hair care, wound care, and over-the-counter pharmaceuticals, with well-recognized brands like Band-Aid, Tylenol, and Neutrogena. Operating globally, the corporation's extensive portfolio and commitment to healthcare innovation make it a pivotal player in the industry, ensuring it remains influential in addressing worldwide health challenges and advancing medical technology.
Never miss another JNJ filing
Profitelligence watches EDGAR around the clock and alerts you within seconds.